Find market research reports published recently by global market research publishers in our online library. These latest research reports cover industry trends, market size, share and other data analysis information.
|Scooped by peter dj|
Eloctate (Hemophilia A and B) – Forecast and Market Analysis to 2022
The report “Eloctate (Hemophilia A and B) – Forecast and Market Analysis to 2022″ by GlobalData is now available at RnRMarketResearch.com.
Contact email@example.com with “Eloctate (Hemophilia A and B) – Forecast and Market Analysis to 2022 “in subject line and your contact details to purchase this report or get your questions answered.
The competitive landscape of hemophilia A and B recombinant therapy in the US and 5EU is dominated by the use of recombinant FVIII and FIX replacement factors, and patients with severe forms of the disease receive frequent prophylactic infusions beginning from the first one or two years of life and often continuing through adulthood. However, the burden on patients and their families to maintain the prophylactic treatment schedule is high, and there is a significant unmet need for new therapies that can reduce the number of weekly prophylactic infusions and alleviate some of this treatment burden.
Buy a copy of this report by GlobalData @ http://www.rnrmarketresearch.com/contacts/purchase?rname=145258 .
Biogen Idec’s long-lasting recombinant Factor VIII candidate Eloctate is under FDA regulatory review for prophylactic and on-demand treatment for hemophilia A patients. Eloctate aims to change the treatment paradigm by allowing patients to adopt a prophylactic dosing schedule with increased time between infusions.
ScopeOverview of Hemophilia A and B, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.Detailed information on Eloctate including product description, safety and efficacy profiles as well as a SWOT analysis.Sales forecast for Eloctate for the top nine countries from 2012 to 2022.Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan, Argentina and China.
Reasons to buyUnderstand and capitalize by identifying products that are most likely to ensure a robust returnStay ahead of the competition by understanding the changing competitive landscape for Hemophilia A and BEffectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potentialMake more informed business decisions from insightful and in-depth analysis of Eloctate performanceObtain sales forecast for Eloctate from 2012-2022 in top nine countries (the US, France, Germany, Italy, Spain, the UK, Japan, Argentina and China)
Complete report spread across 59 pages available @ http://www.rnrmarketresearch.com/eloctate-hemophilia-a-and-b-forecast-and-market-analysis-to-2022-market-report.html .
Read more on “Eloctate (Hemophilia A and B) – Forecast and Market Analysis to 2022” report below.
Table of Contents
1 Table of Contents 4
1.1 List of Tables 7
1.2 List of Figures 7
2 Introduction 8
2.1 Catalyst 8
2.2 Related Reports 9
2.3 Upcoming Related Reports 11
3 Disease Overview 12
3.1 Etiology and Pathophysiology 12
3.1.1 Etiology 12
3.1.2 Pathophysiology 13
3.1.3 Prognosis and Quality of Life 15
3.2 Symptoms 16
3.2.1 Hemophilia A and B 16
3.2.2 Inhibitors 17
4 Disease Management 18
4.1 Treatment Overview 18
4.1.1 Hemophilia A and B Diagnosis 19
4.1.2 Hemophilia A and B Treatment 19
4.1.3 Inhibitors Diagnosis 21
4.1.4 Inhibitors Treatment 21
5 Competitive Assessment 23
5.1 Overview 23
5.2 Strategic Competitive Assessment 24
6 Opportunity and Unmet Need 28
6.1 Overview 28
6.2 Opportunities Analysis 29
6.2.1 Longer-Lasting Recombinant Factors to Reduce the Frequency of Prophylactic Injections 29
6.2.2 Lower-Cost Recombinant Replacement Therapies 30
6.2.3 Lower Risk of Inhibitor Formation in Previously Untreated Patients 31
6.2.4 More Convenient Drug Administration 31
6.2.5 Oral Formulation of Recombinant Replacement Therapies 32
6.3 Unmet Needs Gap Analysis 32
6.3.1 Long-Acting FVIII Replacement Therapies 32
6.3.2 Gene Therapy Treatments for Hemophilia A and B 33
7 Pipeline Assessment 34
7.1 Overview 34
7.2 Promising Drugs in Clinical Development - Hemophilia A 34
7.3 Promising Drugs in Clinical Development - Hemophilia B 36
7.4 Promising Drugs in Clinical Development - Hemophilia A and B Patients with Inhibitors 38
8 Eloctate (rFVIII-Fc) 39
8.1 Overview 39
8.2 Efficacy 40
8.3 Safety 41
8.4 Dosing and Formulation 41
8.5 Potential Clinical Positioning 42
8.6 Potential Commercial Positioning 43
8.7 Pricing and Reimbursement 43
8.8 SWOT Analysis 44
For further information on “Eloctate (Hemophilia A and B) – Forecast and Market Analysis to 2022” report OR for any other business research / market intelligence need on the ‘Hematology Therapeutics’ market : http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/therapeutics/hematology-therapeutics .
Contact: firstname.lastname@example.org / Call +1 888 391 5441.